NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $3.80 +0.12 (+3.26%) Closing price 04:00 PM EasternExtended Trading$3.78 -0.02 (-0.42%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Voyager Therapeutics Stock (NASDAQ:VYGR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Voyager Therapeutics alerts:Sign Up Key Stats Today's Range$3.71▼$3.9050-Day Range$3.48▼$4.8752-Week Range$2.64▼$5.55Volume571,582 shsAverage Volume560,795 shsMarket Capitalization$229.60 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingModerate Buy Company Overview Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need. The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development. Lead programs target Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS), with the goal of providing long-term, one-time treatments to restore or preserve neuronal function. Voyager’s flagship clinical asset is VY-AADC, an AAV2 vector designed to deliver aromatic L-amino acid decarboxylase directly to regions of the brain affected by Parkinson’s pathology. Founded in 2015 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics collaborates with academic institutions, research hospitals and biopharmaceutical partners to advance its gene therapy programs. The company conducts clinical trials across multiple sites in the United States and Europe, leveraging strategic partnerships to support vector manufacturing, regulatory engagement and trial execution. Voyager is led by a management team with deep expertise in gene therapy, neurology and biopharmaceutical development. Its scientific advisory board comprises leaders in neuroscience research, while its operational staff brings experience in regulatory affairs, clinical operations and process development. The company remains committed to translating cutting-edge science into transformative therapies for patients with debilitating neurological disorders.AI Generated. May Contain Errors. Read More Voyager Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreVYGR MarketRank™: Voyager Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 395th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVoyager Therapeutics has a consensus price target of $16.50, representing about 334.2% upside from its current price of $3.80.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.54) to ($1.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.94% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 8.64.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 2.64%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentVoyager Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Voyager Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $155,993.00 in company stock.Percentage Held by Insiders12.70% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYGR Stock News HeadlinesWhat Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy ProgramsMay 20 at 12:49 AM | finance.yahoo.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026May 13, 2026 | markets.businessinsider.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 22 at 1:00 AM | Porter & Company (Ad)Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026May 13, 2026 | globenewswire.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comSee More Headlines VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $3.93 at the start of the year. Since then, VYGR shares have decreased by 3.3% and is now trading at $3.80. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The firm had revenue of $1.19 million for the quarter, compared to analysts' expectations of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative trailing twelve-month return on equity of 55.97%. When did Voyager Therapeutics IPO? Voyager Therapeutics (VYGR) raised $80 million in an initial public offering (IPO) on Wednesday, November 11th 2015. The company issued 5,000,000 shares at $15.00-$17.00 per share. Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' top institutional investors include Dimensional Fund Advisors LP (1.45%), Renaissance Technologies LLC (0.96%), Altshuler Shaham Ltd (0.45%) and Patriot Financial Group Insurance Agency LLC (0.34%). Insiders that own company stock include Robin Swartz, Nathan D Jorgensen, Peter P Pfreundschuh, Todd Alfred Carter and Sandell Jacquelyn Fahey. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today5/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, VYGR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYGR CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees100Year Founded2014Price Target and Rating Average Price Target for Voyager Therapeutics$16.50 High Price Target$25.00 Low Price Target$8.00 Potential Upside/Downside+334.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.72 million Net Margins-319.61% Pretax Margin-319.27% Return on Equity-55.97% Return on Assets-43.12% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual Sales$40.37 million Price / Sales5.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book1.32Miscellaneous Outstanding Shares60,420,000Free Float52,748,000Market Cap$229.60 million OptionableOptionable Beta1.26 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:VYGR) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredThe Most Important Tech Company in America?One private company holds over $26 billion in government contracts tied to AI warfare and defense systems - an...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
